[1][2] During his career in the pharmaceutical industry, Ruffolo played a significant role in the discovery and/or development of a number of marketed products, including dobutamine (Dobutrex) for the acute management of congestive heart failure, and eprosartan (Teveten) for hypertension.
He holds the patent for the discovery of use of carvedilol (Coreg) for the treatment of congestive heart failure which changed the paradigm for the treatment of this devastating disease, and he led the research team that discovered ropinerole (Requip) for Parkinson's Disease.
At Wyeth, Dr. Ruffolo managed an R&D organization of 9,000 scientists with an annual budget in excess of $3 billion.
Ruffolo received a number of prestigious awards, including In 2007, Ruffolo received Degrees Honoris Causa in management engineering from the University of Catania in Sicily, Italy and a Doctorate in science from West Virginia University.
Since retiring from Wyeth/Pfizer, Ruffolo has joined a number of boards, where he consults with early and mid-stage life science companies on the development and commercialization of new pharmaceutical products: